Adicet Bio (STU:1IJA) Total Assets : €221.61 Mil (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Adicet Bio Total Assets?

Adicet Bio's Total Assets for the quarter that ended in Sep. 2024 was €221.61 Mil.

During the past 12 months, Adicet Bio's average Total Assets Growth Rate was -12.20% per year. During the past 3 years, the average Total Assets Growth Rate was -7.00% per year.

During the past 6 years, Adicet Bio's highest 3-Year average Total Assets Growth Rate was 56.10%. The lowest was -7.00%. And the median was 24.55%.

Total Assets is connected with ROA %. Adicet Bio's annualized ROA % for the quarter that ended in Sep. 2024 was -46.61%. Total Assets is also linked to Revenue through Asset Turnover. Adicet Bio's Asset Turnover for the quarter that ended in Sep. 2024 was 0.00.

Adicet Bio Total Assets Historical Data

The historical data trend for Adicet Bio's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adicet Bio Total Assets Chart

Adicet Bio Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

73.43

126.45

299.96

312.17

190.09

Adicet Bio Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Assets	Get a 7-Day Free Trial															218.56	190.09	269.65	249.75	221.61

Adicet Bio Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Adicet Bio's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	156.05	+	34.039
	=	190.09

Adicet Bio's Total Assets for the quarter that ended in Sep. 2024 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2024 )	+	Total Liabilities (Q: Sep. 2024 )
	=	190.589	+	31.022
	=	221.61

Adicet Bio (STU:1IJA) Total Assets Explanation

Total Assets is connected with ROA %.

Adicet Bio's annualized ROA % for the quarter that ended in Sep. 2024 is

ROA %	=	Net Income (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
	=	-109.844	/	( (249.754	+	221.612)	/ 2 )
	=	-109.844	/	235.683
	=	-46.61 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Adicet Bio's Asset Turnover for the quarter that ended in Sep. 2024 is

	Asset Turnover
=	Revenue (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
=	0	/	( (249.754	+	221.612)	/ 2 )
=	0	/	235.683
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Adicet Bio Total Assets Related Terms

Thank you for viewing the detailed overview of Adicet Bio's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Adicet Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adicet Bio Inc (STU:1IJA) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

ACET:USA 0HX7:UK

Address

131 Dartmouth Street, 3rd Floor, Boston, MA, USA, 02116

Website

https://www.adicetbio.com

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Adicet Bio Headlines

No Headlines